Secondary Logo

Journal Logo

Endobronchial Actinomycosis After Airway Stenting

Godfrey, Amanda M. K. MD; Diaz-Mendoza, Javier MD; Ray, Cynthia MD; Simoff, Michael J. MD

Journal of Bronchology & Interventional Pulmonology: October 2012 - Volume 19 - Issue 4 - p 315–318
doi: 10.1097/LBR.0b013e31826a3aed
Case Reports
Free

Actinomycosis is a chronic suppurative infection with filamentous, gram-positive, nonspore forming anaerobic bacteria of the genus Actinomyces. Actinomyces species are commensals of the human oropharynx, gastrointestinal tract, and female genitalia. Involvement of the thorax accounts for 15% to 20% of actinomycosis cases. Thoracic actinomycosis classically presents as an intrapulmonary infection of the alveoli, peribronchial tissue, and/or bronchioles. Endobronchial actinomycosis is a rare condition that has been reported in association with aspiration of a foreign body or broncholithiasis. A critical component in the pathogenesis is disruption of the mucosal barrier, thereby allowing invasion of the microorganisms from aspirated oropharyngeal secretions. Even with a high clinical suspicion, actinomycosis is a diagnostic challenge. The most common symptoms of endobronchial actinomycosis include cough, sputum production, and fever. The disease is often confused with lung cancer, tuberculosis, fungal infections, nocardiosis, and poorly responding pneumonia. The present case highlights the first reported case of endobronchial actinomycosis associated with a covered nitinol endobronchial stent.

Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Henry Ford Hospital, Detroit, MI

Disclosure: M.J.S. reports that he receives royalties from Blackwell Publishing as a textbook editor. In addition, he has served as an expert witness on 1 occasion over the past 36 months and will have meeting expenses covered for the World Congress of Bronchoesophagoscopy at the Cleveland Clinic as he is the vice-chairman for the event. For the remaining authors, there is no conflict of interest or other disclosures.

Reprints: Amanda M. K. Godfrey, MD, Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Henry Ford Hospital, K-17, 2799 West Grand Boulevard, Detroit, MI 48202 (e-mail: agodfre1@hfhs.org).

Received June 11, 2012

Accepted July 17, 2012

Back to Top | Article Outline

CASE REPORT

A 62-year-old woman, former smoker, was evaluated for a subacute nonproductive cough and progressive exertional dyspnea. Initial chest radiography revealed opacification of the right hemithorax with mediastinal shift to the right. Positron emission tomography (PET) computed tomography (CT) revealed increased fluorodeoxyglucose (FDG) uptake within the right hemithorax, with a maximal standardized uptake value of 15.8, corresponding to a bulky soft tissue mass extending from the level of the aortic arch to the right main pulmonary artery. Bronchoscopy revealed that the mass was invading the right mainstem bronchus.

The patient was diagnosed with stage III B (T4, N2, M0) squamous cell carcinoma. She underwent rigid bronchoscopy with mechanical debulking and laser photodessication, in addition; a covered nitinol endobronchial stent was deployed within the right mainstem bronchus and bronchus intermedius to further relieve airway obstruction. Subsequently, daily external-beam radiation therapy with weekly low-dose carboplatin and paclitaxel was administered for 8 weeks. PET-CT completed 18 and 27 months after the conclusion of treatment showed no evidence of recurrent disease.

Thirty-three months after the conclusion of treatment, the patient developed a productive cough associated with fatigue and weight loss. A new 8-mm nodule in the right lower lobe and a stable right suprahilar soft tissue opacity consistent with postradiation change were seen on CT scan of the thorax. PET-CT revealed interval development of mild FDG hypermetabolism in the right infrahilar region posteriorly and inferiorly to the distal portion of the stent (Fig. 1) and in the right lower lobe nodule suspicious for recurrent disease. Bronchoscopy showed concentric soft tissue at the distal portion of the stent, causing 30% obstruction of the airway, which was biopsied. Histopathology was negative for malignancy but revealed chronic active bronchitis with filamentous microorganisms consistent with Actinomyces (Fig. 2). A diagnosis of endobronchial actinomycosis was made and oral Penicillin VK was started. Removal of the covered nitinol endobronchial stent was done by rigid bronchoscopy. Bronchoscopy 8 weeks after the initiation of antimicrobial therapy and stent removal demonstrated patent airway orifices. Pathology from endobronchial biopsies revealed unremarkable peribronchial tissue without evidence of malignancy or Actinomyces. Penicillin VK was discontinued after a total of 12 weeks. Six months later, the patient remained asymptomatic with PET-CT demonstrating only mild residual hypermetabolism (maximal standardized uptake value of 2.5).

FIGURE 1

FIGURE 1

FIGURE 2

FIGURE 2

Back to Top | Article Outline

DISCUSSION

Actinomycosis is a chronic suppurative infection due to filamentous, gram-positive, nonspore forming, anaerobic bacteria of the genus Actinomyces. Actinomyces species are commensals of the human oropharynx, gastrointestinal tract, and female genitalia. Actinomycosis is caused mainly by Actinomyces israelii.1 The organism, Actinomyces, was initially misclassified as a fungus. The word actinomycosis was derived from the Greek terms aktino, which refers to the radiating appearance of a sulfur granule, and mykos, which labels the condition a mycotic disease.2

Actinomycosis occurs worldwide. The reported incidence is approximately 1 out of 300,000 people per year. Most series describe a peak incidence in the fourth and fifth decades.1 The disease is classically divided into 3 types depending on the anatomic site involved: cervicofacial, abdominopelvic, and thoracic. Thoracic actinomycosis typically presents as an intrapulmonary infection and accounts for 15% to 20% of the total burden of disease.3 Endobronchial actinomycosis is rare. A critical component in the pathogenesis is disruption of the mucosal barrier, thereby allowing invasion of the microorganisms from aspirated oropharyngeal secretions.3

Thoracic actinomycosis, in the preantimicrobial era, was reported to extend to the ribs and chest wall causing cutaneous fistulas discharging sulfur granules.1 However, the mode of presentation has now changed with symptoms and physical signs being nonspecific and the disease being commonly confused with lung cancer, pulmonary tuberculosis, fungal infections, nocardiosis, and poorly responding pneumonia.4,5 In endobronchial actinomycosis, the most commonly reported symptoms include cough, sputum production, fever, and hemoptysis.

Rare cases of endobronchial actinomycosis have been reported in association with broncholithiasis, aspirated foreign objects, and without the presence of foreign material.6–9 In a series of 5 patients, in which the diagnosis of bronchogenic carcinoma was suspected, endobronchial actinomycosis was documented without associated broncholithiasis or aspirated foreign objects. Flexible bronchoscopy revealed an obstructive endoluminal mass, often yellow in color, in all patients.10

Endobronchial actinomycosis associated with broncholithiasis likely results from secondary colonization of a preexisting endobronchial broncholith by aspirated Actinomyces organisms with the subsequent inflammatory process enlarging the endobronchial lesion and progressively obstructing the airway.6 In a series of 9 patients, CT of the thorax revealed a proximal endobronchial calcified nodule in all patients and distal postobstructive pneumonic consolidation of the involved lobe or segment in 8 patients.6 Endobronchial actinomycosis has also been reported in association with aspirated chicken bones, a fish bone, teeth, and grape seeds.7 In a review of 11 cases, an obstructive endoluminal mass was found endoscopically in all cases. However, the foreign body was not always detected immediately but subsequently visualized on repeat bronchoscopy 3 to 4 months after initiation of antimicrobial therapy.7

Actinomycosis is a diagnostic challenge with the disease being suspected in <7% of patients who are found to have the infection.1,3 Even when the clinical suspicion is high, microbiological confirmation remains difficult. Physiological saline solution, commonly used for bronchoalveolar lavage, has been reported to inhibit growth of Actinomyces species.2 Following proper technique in collecting and delivering specimens for anaerobic culture is critical. Actinomyces stain in tissue with Gomori methenamine silver. Histopathology reveals acute inflammation surrounded by fibrosing granulation tissue. Sulfur granules, round or oval basophilic masses with a radiating arrangement of eosinophilic clubs on the surface, are highly suggestive but not pathognomonic for actinomycosis.2 Transbronchial biopsy may distort the morphologic appearance of sulfur granules. Correlation of clinical, radiologic, and pathologic findings with appropriate response to antimicrobial therapy is imperative for accurate diagnosis.

Antimicrobial treatment of thoracic actinomycosis has been based on extensive clinical experience rather than randomized controlled trials. The typical treatment consists of 2 to 6 weeks of intravenous penicillin followed by oral therapy for 6 to 12 months. Tetracycline (for penicillin allergic patients), erythromycin (for pregnant women), and clindamycin are suitable alternatives.11 A retrospective case series revealed that a substantial proportion of patients with thoracic actinomycosis can be successfully treated with <3 months of antibiotic therapy.11 In addition, a patient with endobronchial actinomycosis secondary to an aspirated fish bone achieved complete clinical and radiologic recovery after removal of the foreign body and a 1-month course of oral amoxicillin.12 Treatment for endobronchial actinomycosis must be individualized based on the initial burden of disease, performance of bronchoscopic removal of the causative foreign body, and the clinical and radiologic responses to therapy but likely does not require traditional long-term antimicrobial therapy.

In conclusion, this case is unique in that it is the first reported case of endobronchial actinomycosis associated with a covered nitinol endobronchial stent. It also highlights the importance of mucosal barrier disruption in the pathogenesis of endobronchial actinomycosis. Nitinol, an intermetallic alloy of nickel and titanium, exhibits good biocompatibility and was an unlikely contributor to the development of actinomycosis.13 Rather, the presence of the endobronchial stent contributed to disruption of the mucosal barrier with the development of inflamed granulation tissue. Therefore, despite the susceptibility of Actinomyces to penicillin, antimicrobial therapy alone would not have been adequate to achieve complete resolution. Removal of the foreign body, the covered nitinol endobronchial stent, was necessary so that the protective mucosal barrier could regenerate, eliminating the nidus for recurrent infection. In addition, it demonstrates that one must be cognizant that endobronchial actinomycosis can mimic bronchogenic carcinoma and cause FDG hypermetabolism on PET-CT. It highlights that short-term oral penicillin, opposed to long-term antimicrobial therapy, in combination with bronchoscopic removal of the stimulus for infection, is a successful treatment modality for endobronchial actinomycosis associated with a foreign body. Finally, it emphasizes the importance that pulmonologists must now recognize actinomycosis as a potential cause of endobronchial disease in patients with endobronchial stents.

Back to Top | Article Outline

REFERENCES

1. Yildiz O, Doganay M. Actinomycoses and Nocardia pulmonary infections. Curr Opin Pulm Med. 2006;12:228–234
2. Mabeza GF, Macfarlane J. Pulmonary actinomycosis. Eur Respir J. 2003;21:545–551
3. Weese W, Smith I. A study of 57 cases of actinomycosis over a 36-year period. A diagnostic ‘failure’ with good prognosis after treatment. Arch Intern Med. 1975;135:1562–1568
4. Kim YS, Suh JH, Kwak SM, et al. Foreign body-induced actinomycosis mimicking bronchogenic carcinoma. Korean J Intern Med. 2002;17:207–210
5. Lee SH, Shim JJ, Kang EY, et al. Endobronchial actinomycosis simulating endobronchial tuberculosis: a case report. J Korean Med Sci. 1999;14:315–318
6. Kim TS, Han J, Koh WJ, et al. Endobronchial actinomycosis associated with broncholithiasis: CT findings for nine patients. Am J Roentgenol. 2005;185:347–353
7. Chouabe S, Perdu D, Deslée G, et al. Endobronchial actinomycosis associated with foreign body: four cases and a review of the literature. Chest. 2002;121:2069–2072
8. Ho JC, Ooi GC, Lam WK, et al. Endobronchial actinomycosis associated with a foreign body. Respirology. 2000;5:293–296
9. Kim TS, Han J, Koh WJ, et al. Thoracic actinomycosis: CT features with histopathologic correlation. Am J Roentgenol. 2006;186:225–231
10. Ariel I, Breuer R, Kamal NS, et al. Endobronchial actinomycosis simulating bronchogenic carcinoma. Diagnosis by bronchial biopsy. Chest. 1991;99:493–495
11. Choi J, Koh WJ, Kim TS, et al. Optimal duration of IV and oral antibiotics in the treatment of thoracic actinomycosis. Chest. 2005;128:2211–2217
12. Maki K, Shinagawa N, Nasuhara Y, et al. Endobronchial actinomycosis associated with a foreign body—successful short-term treatment with antibiotics. Intern Med. 2010;49:1293–1296
13. Stoeckel D, Pelton A, Duerig T. Self-expanding nitinol stents: material and design considerations. Eur Radiol. 2004;14:292–301
Keywords:

endobronchial actinomycosis; covered endobronchial stent; thoracic actinomycosis; foreign-body aspiration

© 2012 Lippincott Williams & Wilkins, Inc.